Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet syndrome, with the deal worth $550m. Up to 38,000 people in the US, UK, EU and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback